Streinu-Cercel, A.; Preotescu, Liliana; Streinu-Cercel, Anca; Cӑlin, Ruxandra; Budulac, Anca; Streinu-Cercel, Oana
September 2009
Therapeutics, Pharmacology & Clinical Toxicology;2009, Vol. 13 Issue 3, p281
Academic Journal
Introduction. An adequate diagnosis of fibrosis in viral hepatitis C is essential for treatment decisions and disease prognostic. Because of the limitations of liver biopsy, noninvasive explorations of fibrosis are frequently employed nowadays. This study's aim was th at of evaluating the correlation between the currently available noninvasive standardized tests (FibroTest and FibroScan) and liver biopsy. Material and methods The study cluster consisted of n=26 naïve patients with chronic viral hepatitis C, which underwent antiviral treatment in the National Institute for Infectious Diseases "Prof. Dr. Matei Bals", Bucharest, Romania, during December 2007 - December 2008. Fibrosis was assessed before commencement of the combined treatment (Pegylated Interferon and Ribavirin) by means of liver biopsy, FibroScan and FibroTest and at 48 weeks th rough FibroScan and FibroTest, verifying the statistic correlation of the results acquired th rough the three methods. Results. The values obtained th rough FibroScan ranged between min 4.9 kPa and max 49.1kPa, respecting the validation criteria IQR<30%, SR>60%. The cut-offvalues were: 7.1kPa for F2, 9.5 kPa for F3 and 12.5 kPa for F4. FibroScan and FibroTest results have correlated in a 92% percentage. When the results of FibroScan and FibroTest coincided, biopsies were statistically correlated at AUROC 0.79 for F>= 2, 0.91 for F>=3 and 0.97 for F>=4. The frequency of grounds for discrepancy of the three evaluation methods was: LB 5%, Fibroscan 2%, Fibrotest 1%. Conclusions. FibroScan is a new, simple, noninvasive method which is available at the patient's bedside for quick evaluation of liver fibrosis degree with accuracy similar to th at of the FibroTest, especially for the assessment of significant hepatic fibrosis (F2-F4). The combined use of FibroScan and FibroTest results for the evaluation of hepatic fibrosis degree can permit avoiding liver biopsy in a considerable number of patients with chronic viral hepatitis C.


Related Articles

  • The use of peginterferon in monotherapy or in combination with ribavirin for the treatment of acute hepatitis C. Nunnari, G.; Montineri, A.; Portelli, V.; Savalli, F.; Fatuzzo, F.; Cacopardo, B. // European Review for Medical & Pharmacological Sciences;2012, Vol. 16 Issue 8, p1013 

    BACKGROUND, Acute hepatitis C becomes chronic in 50% of cases. Early treatment seems to be effective in eradicating HCV infection, although no clear recommendations are available in terms of time of initiation, regimen and duration of therapy. We report a retrospective review of 48 patients with...

  • New guidelines for managing hepatitis C. Cerrato, Paul // Contemporary OB/GYN;Oct2002, Vol. 47 Issue 10, p100 

    Discusses guidelines from the U.S. National Institutes of Health for managing hepatitis C as of October 2002. Recommended test for patients with clinical liver disease; Effectiveness of combined interferon/ribavirin therapy in the treatment of hepatitis; Factors that should be considered in...

  • Study identifies when to re-treat hepatitis C and in which patients. Mayor, Susan // British Journal of Hospital Medicine (17508460);Jun2008, Vol. 69 Issue 6, p319 

    The article reports on the international REPEAT randomized clinical trial involving 942 patients with detectable levels of hepatitis C (HCV) RNA after 12 weeks of treatment with peginterferon alfa-2b and ribavirin. It was observed that patients who show a substantial decrease in HCV RNA have the...

  • Short-Term Treatment and Sustained Virologic Response in Two Chronic Hepatitis C Cases. Erol, Serpil; Parlak, Mehmet // Medical Journal of Trakya University / Trakya Universitesi Tip F;2010, Vol. 27 Issue 1, p92 

    The standard treatment for chronic hepatitis C infection is the combination of pegylated interferon-alpha (Peg-IFN-α) and ribavirin for 48 weeks in patients infected with genotype-1. In genotype-2 or -3 infections, treatment by either conventional IFN-α and ribavirin or Peg-IFN-α with...

  • A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation. Ahmad, Waqar; Ijaz, Bushra; Gull, Sana; Asad, Sultan; Khaliq, Saba; Jahan, Shah; Sarwar, Muhammad T.; Kausar, Humera; Sumrin, Aleena; Shahid, Imran; Hassan, Sajida // Virology Journal;2011, Vol. 8 Issue 1, p53 

    Background: Chronic HCV is one of the major causes of morbidity and mortality in the present day world. The assessment of disease progression not only provides useful information for diagnosis and therapeutic supervision judgment but also for monitoring disease. Different invasive and non...

  • Diagnostic value of the APRI index for liver fibrosis in a Chinese patients population with chronic hepatitis C acquired from blood transfusion. LEI, Chengduo; REN, Yan; ZHENG, Sujun // Journal of Clinical Hepatology / Linchuang Gandanbing Zazhi;May2013, Vol. 29 Issue 5, p343 

    Objective To evaluate the diagnostic efficacy of various newly developed non - invasive flbrotic predictive models based on meas-urements of common biochemical indices in a group of ethnic Chinese patients with long - standing chronic hepatitis C ( CHC ) infection ac-quired by transfusion....

  • Noninvasive Serum Fibrosis Markers for Screening and Staging Chronic Hepatitis C Virus Patients in a Large US Cohort. Holmberg, Scott D.; Lu, Mei; Rupp, Loralee B.; Lamerato, Lois E.; Moorman, Anne C.; Vijayadeva, Vinutha; Boscarino, Joseph A.; Henkle, Emily M.; Gordon, Stuart C. // Clinical Infectious Diseases;Jul2013, Vol. 57 Issue 2, p240 

    Authors review 2 (FIB-4 and APRI) systems relying on more easily obtainable serum and cell biomarkers for liver biopsies to stage liver disease. This would be an important step in opening treatment and care of uncomplicated hepatitis C virus–infected patients.Background. Liver biopsy...

  • Extent of liver inflammation in predicting response to interferon & Ribavirin in chronic hepatitis C patients: a cohort study. Mirza, Shirin; Siddiqui, Amna Rehana; Hamid, Saeed; Umar, Muhammad; Bashir, Shaheena // BMC Gastroenterology;2012, Vol. 12 Issue 1, p71 

    Background: Liver inflammation due to HCV infection leads to fibrosis, which is an independent predictor of treatment response to interferon therapy in Chronic Hepatitis C (CHC) patients. This relationship has not been studied for liver inflammation on pretreatment liver biopsy and End of...

  • IL28B polymorphism is associated with fatty change in the liver of chronic hepatitis C patients. Ohnishi, Mayu; Tsuge, Masataka; Kohno, Tomohiko; Zhang, Yizhou; Abe, Hiromi; Hyogo, Hideyuki; Kimura, Yuki; Miki, Daiki; Hiraga, Nobuhiko; Imamura, Michio; Takahashi, Shoichi; Ochi, Hidenori; Hayes, C.; Tanaka, Shinji; Arihiro, Koji; Chayama, Kazuaki // Journal of Gastroenterology;Jul2012, Vol. 47 Issue 7, p834 

    Background: Several single nucleotide polymorphisms (SNPs) within the interleukin 28B ( IL28B) locus are associated with sustained viral response in chronic hepatitis C (HCV) patients who were treated with pegylated interferon (PEG-IFN) plus ribavirin (RBV) combination therapy. Recently, an...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics